Workflow
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
RAREUltragenyx Pharmaceutical(RARE) ZACKS·2025-02-13 23:30

Core Insights - Ultragenyx reported revenue of 164.88millionforthequarterendedDecember2024,reflectinga29.4164.88 million for the quarter ended December 2024, reflecting a 29.4% increase year-over-year [1] - The company's EPS was -1.39, an improvement from -1.52inthesamequarterlastyear[1]−RevenueexceededtheZacksConsensusEstimateof1.52 in the same quarter last year [1] - Revenue exceeded the Zacks Consensus Estimate of 163.23 million by 1.01%, while EPS fell short of the consensus estimate of -1.24by12.101.24 by 12.10% [1] Revenue Breakdown - Product sales for Dojolvi reached 31.10 million, surpassing the estimated 27.23million,markinga33.627.23 million, marking a 33.6% increase year-over-year [4] - Evkeeza generated 10.37 million, slightly below the 10.65millionestimate,butshowedasignificantyear−over−yearincreaseof393.510.65 million estimate, but showed a significant year-over-year increase of 393.5% [4] - Mepsevii sales were reported at 7.98 million, below the average estimate of 8.91million[4]−Totalproductsalesamountedto8.91 million [4] - Total product sales amounted to 71.87 million, compared to the average estimate of 83million,representinga39.183 million, representing a 39.1% year-over-year increase [4] - Crysvita sales were 22.42 million, significantly lower than the estimated 35.76million[4]−Non−cashcollaborationroyaltyrevenuewasreportedat35.76 million [4] - Non-cash collaboration royalty revenue was reported at 93.01 million, exceeding the average estimate of $71.60 million [4] Stock Performance - Ultragenyx shares have returned +6% over the past month, outperforming the Zacks S&P 500 composite's +3.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]